The IN.PACT Admiral drug-coated balloon can now be used as a treatment for in-stent restenosis in patients with peripheral artery disease. In-stent restenosis occurs when plaque builds up in and around a stent placed in an artery to restore blood flow.
“We are experiencing a paradigm shift in treating patients with complex PAD,” said John Laird, MD, interventional cardiologist at UC Davis Medical Center in Sacramento, Calif., and co-principal investigator for a clinical trial on the device. “Until now physicians have had limited treatment options to address patients with [in-stent restenosis]. The FDA’s approval of IN.PACT Admiral DCB allows us to treat patients with a durable, proven and safe technology.”
More articles on supply chain:
House panel calls on Mylan CEO to explain EpiPen prices at Sept. 21 hearing Market exclusivity main factor in high drug prices, study finds
US faces shipping container shortage following Hanjin bankruptcy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
